MEDICILON Supports Strategic Partner SinoThera's New-Generation DPP-4 Inhibitor Sentagliptin Phosphate for Market Approval

Dec 12, 2024 07:31 CST Updated 07:31

Medicilon

Preclinical Comprehensive R&D Services CRO

CGeneTech

Small Molecule Innovative Drug Developer

Recently, Shengshi Taike Biopharmaceutical Technology (Suzhou) Co., Ltd. (hereinafter referred to as "CGeneTech") independently developed Class 1 innovative drug, Senaglipitin Phosphate Tablets (formerly known as: Sengliptin Phosphate Tablets), which has been officially approved for marketing in China.

As a strategic partner of CGeneTech, Shanghai Medicilon Inc. (hereinafter referred to as "Medicilon")Provided comprehensive preclinical research services for Sengliptin in compliance with GLP standards, including pharmacodynamics studies, pharmacokinetics studies, safety evaluations, and biomarker bioanalysis for Phase I clinical trials., and demonstrates the reliability of a research system with highly consistent preclinical and clinical experimental data, laying a solid foundation for the successful launch of Cenagliflozin Tablets.

A New Generation of Highly Selective DPP-4 Inhibitor: Cengliptin Tablets

Clinical Data Confirms "Best in Class"

Sengliptin, a New Generation Highly Selective DPP-4 Inhibitor Independently Developed by CGeneTech, is Applicable for Improving Blood Glucose Control in Adult Patients with Type 2 Diabetes

The successful approval and market launch of Sengliptin not only demonstrates the outstanding strength of CGeneTech in the field of hypoglycemic drug research and development but also validates the critical value of the high-quality and efficient services provided by Medicilon in advancing the process of drug innovation.

MEDICILON

MedicilonEndocrine and Metabolic Disease Models

Continuously Accelerate the R&D of Innovative Drugs

In the field of metabolic disease research, Medicilon has accumulated extensive experience and effective animal models, establishing a variety of animal models for diseases including obesity and diabetes, hyperuricemia, fatty liver, NASH (non-alcoholic steatohepatitis), and liver fibrosis, providing strong support for drug development. Additionally, Medicilon offers multiple diabetes and obesity models for evaluating GLP-1 drugs, providing comprehensive one-stop preclinical biopharmaceutical R&D services for GLP-1 drugs, covering drug discovery, pharmaceutical research, pharmacodynamics, pharmacokinetics, and safety assessments. As of April 2024, Medicilon has successfully supported eight GLP-1 drugs in gaining approval to enter clinical trial stages.

Medicilon congratulates CGeneTech on its significant breakthrough in the field of diabetes treatment and looks forward to CGeneTech launching more innovative drugs that benefit human health. Medicilon will continue to uphold the service philosophy of "innovation-driven, quality first," continuously iterate and innovate R&D service technologies and platforms, and provide more professional and efficient preclinical R&D services to pharmaceutical companies worldwide.

About CGeneTech

Shengshi Taike Biopharmaceutical Technology (Suzhou) Co., Ltd. is a biotechnology company at the commercialization stage, with its core product, the Class 1 innovative drug Sengliptin (formerly known as Stegliptin), successfully approved for marketing. Founded in 2010 in Suzhou Industrial Park, the company's core team has decades of international experience in the entire lifecycle of pharmaceuticals and is committed to the research and industrialization of high-quality and differentiated small-molecule innovative drugs. Leveraging an integrated drug development technology platform and diverse commercial perspectives, the company has established a rich pipeline of innovative drugs covering areas such as diabetes treatment, cancer therapy, and autoimmune diseases.

Live Broadcast Preview

Previous Recommendations

Medicilon Helps |Gmax Biopharm KRAS G12C Inhibitor FuzoradenApproved for Marketing ➠

Medicilon Helps |Zhengda Tianqing Innovative Drug BemotuzumabApproved for Marketing ➠

Medicilon Helps |China's First Potassium-Competitive Acid Blocker "Keyplasin Tablets" by CoffeepharmaApproved for Marketing ➠

Medicilon Helps |Medicilon Methylglucamine APIApproved for Marketing ➠

About Medicilon

Medicilon (Stock Code: 688202.SH), established in 2004 and headquartered in Shanghai, is committed to providing comprehensive preclinical new drug research services for global pharmaceutical companies, research institutions, and researchers. Medicilon’s one-stop integrated service, supported by strong project management and more efficient, cost-effective R&D solutions, helps clients accelerate the new drug development process. Services cover the entire process of preclinical new drug research, including drug discovery, pharmaceutical research, and preclinical studies. By the end of June 2024, Medicilon has provided drug R&D services to over 2,000 customers worldwide and has participated in the development of new drugs and generic drug projects.490The IND has been approved for clinical trials, growing together with high-quality customers both in China and abroad. Medicilon will continue to focus on a global perspective, concentrate on innovation in China, and contribute to human health!